Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study
Authors:
- 30 March 2023
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 102 (5) , 1149-1158
Abstract
Yttrium-90 ibritumomab tiuxetan (90YIT) is a radioimmunotherapy agent in which the radioisotope yttrium-90 is bound to ibritumomab via tiuxetan as a chelating agent, and is used for relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma (rr-B-NHL). We conducted a joint study to evaluate the clinical outcome of 90YIT. The J3Zi study is composed of data from patients receiving 90YIT for rr-B-NHL from the top three institutions with 10 years of 90YIT treatment experience from October 2008 to May 2018 in Japan. The efficacy, prognostic factors and safety of 90YIT were retrospectively evaluated. Data from 316 patients were analyzed; the mean age was 64.6 years and the median number of prior treatments was 2. The median PFS was 3.0 years, the final OS rate was over 60%, and the median OS was not reached during the study period. Significant factors influencing PFS were sIL-2R ≤ 500 (U/mL) and no disease progression within 24 months of first treatment. Significant factors influencing OS were number of prior treatments ≤ 2 and sIL-2R ≤ 500 (U/mL). The PFS and OS rates were found to be significantly higher in the late half era (2013 to 2018) than in the early half era (2008 to 2013) during the study period. Prognosis following 90YIT treatment was improved in the late half era compared to the early half era. As treatment using 90YIT increased, administration of 90YIT shifted to the earlier treatment line. This may have contributed to the improvement of prognosis found in the late era. (UMIN000037105).Keywords
Funding Information
- Mundiharma K.K
This publication has 33 references indexed in Scilit:
- Clinical Significance of sIL-2R Levels in B-Cell LymphomasPLOS ONE, 2013
- Japanese phase II study of90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphomaCancer Science, 2009
- Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)The Lancet Oncology, 2008
- Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up studyHaematologica, 2008
- Safety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's LymphomaCancer Biotherapy and Radiopharmaceuticals, 2007
- Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan RadioimmunotherapyJournal of Clinical Oncology, 2007
- Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphomaLeukemia & Lymphoma, 2006
- Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignanciesCancer Detection Prevention, 2005
- The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entitiesPathology International, 2000
- Stage I and II non-hodgkin's lymphomas: Long-term results of radiation therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1989